Flexion Therapeutics, Inc. announced initial findings from its ongoing Phase 3b, open-label study to evaluate the repeat administration of ZILRETTATM (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthritis (OA) of the knee. The data show that of the 205 evaluable patients enrolled in the study, 95% (195/205) experienced clinical benefit by Week 12 following the initial injection of ZILRETTA, as determined by self-assessment and with the agreement of their physician. Furthermore, to date 90% (176/195) of eligible patients have received a second dose of ZILRETTA between Weeks 12 and 24, with three patients still pending repeat administration. The primary endpoint of the trial is overall safety and general tolerability of repeat administration of ZILRETTA in patients with symptomatic OA of the knee. Participants received an initial intra-articular injection of ZILRETTA followed by evaluation at Weeks 12, 16, 20 or 24 to determine their eligibility for a second injection. Repeat administration occurred when, in the opinion of the patient and physician, the patient benefited from and tolerated the initial administration without safety concerns and was clinically indicated to receive additional treatment.